Fresenius Kabi, a pharmaceutical company based in Illinois, has initiated a nationwide recall of one lot of an arthritis injection medication due to the presence of glass particles.
The recall applies to Tyenne (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials, the company said in an announcement published by the Food and Drug Administration on Aug. 11.
The item can be identified by lot number 16UI07 and the National Drug Code 65219-594-20 printed on the label. The injections, shipped between March 3 and 25, have an expiration date of August 2028. The medications were sold to wholesalers, distributors, and customers across the United States….